Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
40.51
+0.53 (1.31%)
Feb 5, 2025, 9:42 AM EST - Market open
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Xenon Pharmaceuticals stock have an average target of 56, with a low estimate of 49 and a high estimate of 65. The average target predicts an increase of 38.25% from the current stock price of 40.51.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 12, 2024.
Analyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 3 |
| Buy | 5 | 4 | 5 | 5 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 10 | 10 | 9 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +30.85% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +30.85% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +48.13% | Nov 13, 2024 |
| Raymond James | Raymond James | Buy Initiates $50 | Buy | Initiates | $50 | +23.44% | Oct 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $53 | Strong Buy | Initiates | $53 | +30.85% | Oct 1, 2024 |
Financial Forecast
Revenue This Year
318.75K
Revenue Next Year
5.42M
from 318.75K
Increased by 1,600.08%
EPS This Year
-3.17
from -2.73
EPS Next Year
-3.73
from -3.17
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 5.3M | 78.8M | 113.5M | |||
| Avg | 318,750 | 5.4M | 41.8M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 24,605.9% | 1,995.0% | |||
| Avg | - | 1,600.1% | 671.6% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.99 | -2.53 | -2.95 | |||
| Avg | -3.17 | -3.73 | -4.03 | |||
| Low | -3.48 | -4.23 | -4.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.